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Abstract
Mucopolysaccharidosis (MPS) is a group of rare disorders that are characterized by intracellular accumulation of 
glycosaminoglycans with subsequent cellular and organ dysfunction. In the Middle East, especially Saudi Arabia, 
higher prevalence of MPS type I was observed compared to reported rates from European countries and the United 
States (U.S). The present work was developed as a part of the Saudi MPS Group’s efforts to address the current 
situation of MPS type I in Saudi Arabia and to reach a national consensus in the management of MPS type I. 
The first “Management of MPS Type I Advisory Board” meeting was held in Riyadh on May 2, 2019, to reflect 
the expert opinions regarding different aspects of MPS type I and develop this manuscript; eight consultants from 
different specialties (medical genetics, pediatric rheumatology, and pediatric endocrinology), representing six Saudi 
institutions, in addition to a global expert in genetics participated in the meeting.
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Introduction
Glycosaminoglycans (GAGs) are long 
unbranched polysaccharides that result from 
the degradation of proteoglycans and undergo 
intracellular digestion inside the lysosome [1]. To 
date, 10 known enzymes participate in the lysosomal 
degradation of GAGs through four different pathways 
[2]. The deficiency in the α-L-iduronidase (IDUA) 
enzyme activity and the intracellular accumulation of 
dermatan and heparan sulfate lead to the development 
of mucopolysaccharidosis (MPS) type I; MPS type I is 
an autosomal recessive disorder with the progressive 
course and multisystem involvement [3]. MPS type I 
is one of the commonest types of MPS and accounts 
for up to 15% of the total cases of MPS [4]. Patients 
with MPS type I can present with characteristic facial 
features, cognitive and neurological impairment, 
hearing impairment, eye problems, cardiomyopathy 
and heart failure, recurrent respiratory infection, 
acute and chronic liver failure, joint contractures 
and cervical instability, and spinal stenosis [3]. In 
addition, patients with MPS type I are at higher risks 
of morbidity and mortality during anesthesia and 
surgical interventions [5].
In the Middle East, especially Saudi Arabia, 
higher prevalence of MPS type I was observed 
compared to reported rates from European countries 
and the United States (U.S) [6]. The high rate of 
consanguinity was postulated as the main contributing 
factors to this high incidence [7]. However, published 
data on the characteristics and treatment patterns of 
MPS patients in Saudi Arabia are still lacking.
The present work was developed as a part of 
the Saudi MPS Group’s efforts to address the current 
situation of MPS type I in Saudi Arabia and to reach 
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a national consensus in the management of MPS 
type I. The first “Management of MPS Type I Advisory 
Board” meeting was held in Riyadh on May 2, 2019, to 
reflect the expert opinions regarding different aspects 
of MPS type I and develop this manuscript; eight 
consultants from different specialties (medical genetics, 
pediatric rheumatology, and pediatric endocrinology), 
representing six Saudi specialized institutions, in 
addition to a global expert in genetics participated in the 
meeting. The consultants discussed different aspects 
of MPS type I management in Saudi Arabia and a 
consensus statement in each aspect was reached by 
the agreement of all attendants.
INCIDENCE OF MPS TYPE I IN SAUDI 
ARABIA
Arab world represents one of the leading 
regions in terms of the incidence of congenital and 
genetic disorders; a growing body of published literature 
reported a notable trend toward higher incidence of 
congenital and genetic diseases, compared to other 
parts of the world [8]. High consanguinity rates which 
reach up to 60% in some regions, high prevalence of 
hemoglobinopathies and metabolic disorders, relatively 
high maternal and parental age, and lack of proper 
genetic screening were reported as contributing factors 
for this high prevalence of genetic disorders in the 
Arab world [8], [9], [10]. In Saudi Arabia, the situation 
appears to be no different as previous retrospective 
studies showed a relatively high incidence of genetic 
diseases such as inborn error of metabolism, including 
MPS type I.
The first retrospective study, which reported 
the incidence of MPS in Saudi Arabia, utilized the 
data from the Saudi Aramco Medical Services 
Organization, which provides comprehensive 
health-care residents of the Eastern Province, was 
conducted. Out of 165,130 live births during this 
period, 248 cases had metabolic diseases with 28 of 
these cases which were MPSs. The most common 
type of MPS was type VI (48% of the total cases) 
with reported birth prevalence of 7.85 per 100,000 
live births. The authors reported that the combined 
incidence of MPS I and MPS IV was 3.62/100,000 
live births, and each accounted for 21% of all 
MPS. Finally, the birth prevalence of MPS III was 
1.8/100,000 (11% of total cases) [6].
In addition, Al-Sannaa et al. performed a 
hospital-based retrospective analysis to evaluate the 
incidence of lysosomal storage disease (LSDs) in the 
Eastern Province of Saudi Arabia between 1983 and 
2016. The incidence of MPSs was 14/100,000 live 
birth; with MPS VI represented the largest subtype [11]. 
Another 13-year retrospective chart review of all live 
birth at the Pediatric Department of King Abdulaziz 
Medical City was 14/100,000 live birth [12].
If we combined the incidence rate of MPS 
in the abovementioned studies, we can conclude 
that the incidence of MPS in Saudi Arabia is near 
30 cases/100,000 live birth, which highlights the notable 
high prevalence of this LSDs in Saudi Arabia, compared 
to other parts of the world. The recent global figure shows 
that the overall birth prevalence of MPS ranges from 1.04 
to 4.8/100,000 live births. For example, Khan et al. [4] 
retrospectively reviewed the number of live births with 
MPS in Switzerland between 1975 and 2008 (nearly 
similar to the study’s period of Moammar et al.); the results 
showed that the combined birth prevalence for diagnosed 
MPS was 1.56/100,000 live births. This incidence was 
quite similar to the reported incidences from Japan and 
other East Asian countries during the same period [13], 
[14], [15]. The incidence of MPS in Saudi Arabia appears 
to be even higher than those reported from other Arab 
countries; a previous report from Tunisia reported an MPS 
birth prevalence of 2.27/100,000 live births. However, 
MPS type I was the most common type of all MPSs (25%) 
with a birth prevalence of 0.63/100,000 live births [16].
However, the experts raised concerns about 
the generalizability of the published retrospective 
studies from Saudi Arabia on the total population of the 
Kingdom; the published reports included the live births 
from one institution or one district of the Kingdom. 
Therefore, there is a need for multicenter studies to 
reflect the real epidemiology of MPS in Saudi Arabia. 
Another concern is the lack of a nationwide newborn 
screening program, which could help to accurate the 
estimation of the incidence of MPS in Saudi Arabia.
Experts’ opinion
To date, there are no reliable data regarding 
the incidence of MPS type I in Saudi Arabia and 
future multicenter studies are needed. In addition, the 
prevalence of an attenuated form of MPS type I is largely 
underestimated in Saudi Arabia due to the absence 
of effective newborn screening program. Therefore, 
implementation of a nationwide newborn screening 
program is essential for accurate estimation of the 
burden of MPS and early diagnosis of the patients.
DIAGNOSIS OF MPS TYPE I IN SAUDI 
ARABIA
Newborn screening program for MPS type I
MPS type I is a chronic, progressive, disorder 
with multisystem affection and fatal disease course. 
Although patients with MPS type I usually present with 
very distinctive physical and cognitive features, most of 
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the patients with MPS are asymptomatic at birth [17]. 
Early diagnosis of MPS type I can potentially reduce 
disease progression and improve the quality of life of 
the patients; thus, newborn screening methods are 
promising modalities for optimizing the outcomes of 
MPS [18]. With the introduction and availability of tandem 
mass spectrometry (MS/MS) methods, it has become 
feasible to implement newborn screening programs 
for many metabolic disorders in both developed and 
developing countries. LSD screening programs have 
gained much attention recently and pilot LSD programs 
were conducted in a number of countries [19], [20]. 
These reports demonstrated that there are a number 
of feasible, effective, and affordable methods for LSD 
screening programs which can be extended to the 
larger population [21].
In the setting of MPS, different methods are 
available for early diagnosis of MPS type I, based on 
detection of the deficient enzyme activity, using dried 
blood spot punches. Conventional fluorimetric methods 
are one of the widely available techniques for the 
detection of enzymatic activity, however, it has limited 
value in testing multiple enzymes simultaneously [22]. 
MS/MS methods, which quantify the lysosomal 
enzyme activity, exhibited high diagnostic accuracy for 
the detection of LSD and high capacity for multiplex 
testing [23]. Recent reports have also introduced new, 
cheap, and feasible MS/MS-based methods for the 
mass detection of MPS type I [24], [25].
Such advances in the diagnostic methods have 
encouraged previous studies to conduct a number of 
MPS I neonatal screening programs, the aim of these 
studies was to evaluate the utility of MPS I neonatal 
screening for inclusion in primary screening programs. 
From 2008 to 2013, a pilot screening program for 
MPS type I was conducted on 35,286 newborns 
from Taiwan. Only two neonates had confirmed the 
diagnosis of MPS type I, the incidence in Taiwan 
estimated from this study is about 1/17,643 [26]. In the 
US, a number of states have conducted a pilot MPS 
screening program. In a comprehensive program for 
LSDs at Missouri, a multiplexing digital microfluidic 
fluorimetric enzymatic assay was used to detect 
Pompe disease, Fabry disease, Gaucher disease, 
and MPS I started in 2013. Out of 43,701 screened 
newborns, a total of three newborns had confirmed 
the diagnosis of MPS type I and seven newborns had 
pseudodeficiency. The incidence rate of 1:14,567 for 
MPS I is in the same range reported in a previous 
Taiwanese pilot study (1:17,643) [27]. Another 
important experience in a newborn screening program 
for LSD including MPS I has been reported in Illinois, 
USA. MS/MS was used to assay for the five LSD-
associated enzymes to detect MPS I, Pompe disease, 
Fabry disease, Gaucher disease, and Niemann-Pick 
disease type A/B. Only one infant was confirmed 
with a positive diagnosis of MPS I and the incidence 
was therefore 1 in 219,793 newborns [28]. Based on 
these findings, the Recommended Uniform Screening 
Panel of the US Department of Health and Human 
Services Secretary’s Advisory Committee on Heritable 
Disorders in Newborns and Children includes Pompe 
and MPS I diseases in the primary panel for neonatal 
screening programs [18].
In Saudi Arabia, there is established national 
newborn screening program since 2005 that covers 
inborn error of metabolism, endocrine disorders, 
congenital heart defects, and hearing loss [29]. A 
recent 7-year retrospective study in 139 hospitals 
reported a high rate of inborn error of metabolism in 
Saudi Arabia compared to other parts of the world [30]. 
However, the inclusion of LSD, including MPS type 
I, in the program has not been discussed yet. The 
experts agreed that there is a need for LSD newborn 
screening program in Saudi Arabia that included MPS. 
However, the lack of reliable data about the incidence 
of MPS in Saudi Arabia is one of the main barriers 
against implementing such a program. One expert in 
our meeting suggested to start the newborn screening 
from the main three research centers in the Eastern 
provenance to provide data about the incidence rates 
of MPS; the results of such survey can open the 
window for implementation of nationwide screening 
program directed for MPS.
Diagnosis of MPS type I
The diagnosis of MPS type I depends on the 
detection of GAG in urine and significant deficiency in 
the activity of IDUA enzyme. In patients with suggestive 
clinical features, the urinary GAG level is evaluated; 
however, normal levels of urinary GAG do not rule out 
the diagnosis of MPS. Although many methods are 
available for the measurement of GAG concentration, 
dimethyl methylene blue is one of the standard tests for 
the quantification of urinary GAG [17]. On the other hand, 
the identification of the type of accumulated GAG can 
be done using chromatography or electrophoresis [31]. 
Alongside biochemical analysis, the molecular tests 
play a critical role in the identification of the genotype of 
MPS; knowing the genotype could potentially aid in the 
identification of the phenotype, genetic counseling, and 
prenatal diagnosis [32].
The experts stated that only a few institutions in 
Saudi Arabia provide urinary GAG measurements and 
many samples are sent abroad for assessment. This 
can increase the risk of false results due to malpractice 
during handling and transportation.
Experts’ Opinion
There are a lot of local barriers for newborn 
screening in Saudi Arabia. The main barrier is the lack 
of clear data about the incidence rate. Therefore, there 
is a need to provide reliable data about the incidence of 
MPS type I before implementing newborn screening of 
MPS in Saudi Arabia. The availability of treatment for 
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MPS is critical in making newborn screening effective. 
Health-care providers may play a role in providing the 
treatment at an affordable cost in different centers in 
Saudi Arabia. The experts also agreed that there is a 
need for Saudi consensus regarding the diagnosis 
and treatment of MPS in Saudi Arabia. The consensus 
should be comprehensive and involve all specialties that 
deal with MPS to share their ideas and suggestions. All 
key players must be invited to this type of meeting. The 
meeting can be conducted in the form of national MPS 
day. Another interesting idea is to develop a national 
day for rare disease in which experts get together and 
hence move forward.
Management of MPS Type 1 in Saudi Arabia
Ideally, effective treatment of MPS type I 
should be able to prevent the intracellular accumulation 
of GAG, slow disease progression, and restore enzyme 
activities. There are few treatment options available for 
the management of MPS type 1. In the early 1980s, 
hematopoietic stem cell transplantation (HSCT) was 
introduced for the treatment of MPS type I, especially 
infants with Hurler syndrome [33]. The previous reports 
have shown that early introduction of HSCT before the 
age of two can significantly prolong patients’ survival 
and slow neurological deterioration [34]. However, 
HSCT is an invasive procedure with a high risk of 
mortality and morbidity; thus, only severe cases are 
candidates for HSCT [35].
More recently, enzyme replacement therapy 
(ERT) with laronidase (Aldurazyme®, BioMarin 
Pharmaceutical, and Genzyme, a Sanofi Company) 
has emerged as a promising modality for MPS 
management. In 2003, the laronidase was the first 
ERT to be approved for the management of MPS 
type I without neurological involvement, as weekly 
intravenous infusion [36]. Conventional ERT has been 
approved in many countries, including the United 
States, Canada, EU, and Japan, as a treatment 
option for patients who have a confirmed diagnosis 
of MPS I. Clinical studies and case reports showed a 
significant reduction in urinary GAG and liver volume 
after laronidase treatment, however, the impact of 
treatment on cardiac or respiratory involvement [37]. 
Alongside these two options, patients may benefit from 
symptomatic and supportive therapy such as surgical 
intervention and speech therapies [36].
Recently, gene therapy was introduced as one 
of the promising options for many inherited diseases 
including MPS. The modality is based on delivering the 
defective gene to the affected cells through a specific 
vector or injection [38]. As CNS involvement appears to 
be resistant for ERT, current research for gene therapy is 
mainly directed at the neurocognitive and musculoskeletal 
levels [39]. Other novel experimental therapies for MPS 
include substrate reduction therapy, anti-inflammatory 
therapy, and pharmacological chaperone therapy.
Experts’ opinion
There is a need for global effort to provide 
affordable drugs for patients with MPS. The Saudi 
ministry of health can negotiate with pharmaceutical 
companies to provide the ERT at affordable price, even 
as part of an insurance plan.
Discussion
Saudi Arabia is the largest country in the 
Arabian peninsula, with a population of more than 
28 million [40]. Despite health care being free to Saudi 
citizens, a number of potential barriers to health-care 
access and individual health-care seeking have been 
reported [41], [42]. While MPS is a rare disease, its 
incidence in Saudi Arabia appears to be higher than 
other parts of the world. Nevertheless, no previous 
nationwide study was conducted to provide reliable 
data regarding the incidence and characteristics of 
Saudi patients with MPS. There is a scarcity in the 
published literature regarding the treatment patterns 
and outcomes of MPS in Saudi Arabia as well.
The Saudi MPS Group’s held a consensus 
meeting to gather views from a panel of Saudi experts 
on current trends and practice regarding MPS in Saudi 
Arabia and to compare their views with current global 
trends and practice. Panel members highlighted the 
need for a central, unified, and updated national registry 
to monitor the current trends of MPS in the Kingdom.
Although uGAG measurement and molecular 
testing were considered an essential diagnostic tool by 
the panel members, many Saudi health-care facilities 
do not have access to uGAG tests and many samples 
are sent abroad for testing; thus, average time for MPS 
diagnosis and referral from first presentation may be 
prolonged with high possibility of false results due to 
malpractice during sample handling and transportation. 
Issues around the availability of drugs and their 
costs have been also raised by the experts. Finally, 
the panel members recommended the development 
of educational and quality improvement programs 
to improve physician’s knowledge and awareness 
about MPS. 
Conclusions and Recommendations
a. There are no reliable data regarding the 
incidence of MPS type I in Saudi Arabia, future 
multicenter studies are needed
b. The prevalence of an attenuated form of MPS 
type I is underestimated in Saudi Arabia
F - Review Articles Narrative Review Article
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c. There is a need to increase the awareness 
among the primary care physicians and 
pediatricians about MPS, particularly the 
attenuated form
d. Early diagnosis is critical for patients with 
MPS type I to effectively slow down disease 
progression
e. There is a need to provide reliable data 
about the incidence of MPS type I before 
implementing newborn screening of MPS in 
Saudi Arabia
f. The availability of treatment for MPS is critical 
in making newborn screening effective
g. There is a need for Saudi consensus regarding 
the diagnosis and treatment of MPS in the 
kingdom
h. The consensus should be comprehensive 
and involve all specialties that deal with MPS 
to share their ideas and suggestions. All key 
players must be invited to this type of meeting. 
The meeting can be conducted in the form of 
national MPS day
i. There is a need for a national day for rare 
diseases in which experts can gather, interact 
together, share their experiences, and discuss 
the recent updates
j. There is a need for global efforts to provide 
affordable drugs for patients with MPS. The 
Saudi ministry of health can negotiate with 
pharmaceutical companies to provide drugs 
with affordable prices, even as a part of an 
insurance plan.
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